High-grade Serous Ovarian Cancer (HGSOC)HGSOC PatientsThe aim of this study was to assess the correlation between BRCA mutation status and disease presentation, treatment strategy, and survival in a multicenter series of recurrent high-grade serous ovarian cancer (HGSOC) women. A consecutive ...
recurrent high-grade serous ovarian cancer. Although the threshold for statistical significance was not met, a numerical OS advantage was seen, irrespective ofBRCAm status, despite
High-grade serous ovarian cancer (HGSOC) is the most frequent and fatal malignancy among gynecological cancers, with a 10-year survival rate of less than 30% [1,2]. Due to the high recurrence and metastasis rate, about 80% of patients tend to recur despite proper management (surgery and ...
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK-A16... abirateroneandrogen receptorCYP17 inhibitorlow grade serousovarian cancerBackground: Recurrent epithelial ovarian cancer (EOC) remains difficult ...
319–322Viral vectors with recombinant peptides such as CEA/MUC1 or NY-ESO-1 have been added to the list of cancer vaccines studied in OC.323–325High grade serousovarian cancer(HGSOC) accounts for up to 80% of OC death and >90% of HGSOCs harbor a p53 mutation.326Overlapping SLPs ...
We conducted a Phase 1 study to evaluate safety and activity of olaparib tablets and oral cyclophosphamide.Patients had metastatic breast cancer (BC) or recurrent high-grade serous ovarian cancer (HGSOC), performance status 0–2, and ≤3 lines of prior therapy. Patients were treated using a ...
aOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Olaparib在有周期性高等级浆液或不足被区分的卵巢癌或三倍消极乳腺癌的病人: 阶段2,多中心, open-label,非被随机...
reviewed by Stephen Hillier and Barbara Vanderhyden)High-grade serous ovarian cancer (HGSC) is among the most lethalforms of cancer in women. Excessive genomic rearrangements,which are expected to create fusion oncogenes, are the hallmarkof this cancer. Here we report a cancer-specific gene fusion...
This was a trial of patients with platinum-sensitive recurrent ovarian cancer, with the emphasis on high-grade serous ovarian cancer. Patients who responded to platinum [chemotherapy] were then randomly assigned 2:1 to either the oral PARP inhibi...
In particular embodiments, the chimeric RNA is useful for methods of treatment, diagnosis, and/or prognosis as they relate to ovarian cancer, or therapy therefor, including at least high-grade serous carcinoma.YEN, LaisingKANNAN, Kalpana